This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Royalty Pharma plc
11/4/2026
Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma third quarter 2026 earnings conference call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.
Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's third quarter results. You can find the press release with our earnings results and slides to this call on the investors page of our website at royaltypharma.com. On slide two, I'd like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from the statements. We refer you to our most recent 10-K on file with the FCC for description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial results and the reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. And with that, please advance to slide three. Our speakers on the call today are Pablo Legorreta, Chief Executive Officer and Chairman of the Board, Marshall Urist, EVP, Head of Research and Investments, and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights after which Marshall will provide a portfolio update and Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session when we'll be joined by Chris Hite, Chairman, Partnering and Investment. And with that, I'd like to turn the call over to Pablo.
Thank you, George, and welcome to everyone on the call. It gives me great pleasure to report another strong quarter in 2026 as we execute towards our goal to be the premier capital allocator in life sciences with consistent compounding growth. Slide five summarizes our strong business momentum in the third quarter. Starting with the financials, we delivered 9% growth in portfolio receipts, our top line, and also in royalty receipts, which are our recurring cash flows. On a year-to-date basis, royalty receipts have grown by 12%, reflecting the strength of our diversified portfolio of high-quality royalties. We also maintain attractive returns in our business, with return on invested capital of 14.3% and return on invested equity of 20.2%. By combining strong growth and superior returns, we're confident we have a clear path to drive shareholder value creation. Turning to capital allocation, we have deployed $1.6 billion of capital so far this year, with an announced value of $1.9 billion. Most recently, we acquired a royalty on Arcutis Sorib, an approved therapy for immune diseases of the skin. We also acquired a royalty on Takeda's Membrilo, a potential blockbuster therapy for rare blood disorders, Polycystemia Vera. as we look ahead our deal pipeline remains robust supported by continued powerful fundamental tailwinds under our value-driven capital location framework we also return close to 590 million to shareholders in dividends and share repurchases in the first nine months of the year moving to our portfolio we're excited to see a number of positive clinical and regulatory updates which we expect to support our growth over the medium to long term Our partner Revolution Medicines received FDA approval and a positive regulatory opinion in Europe for razonque in pancreatic cancer. CEVA also received FDA approval for its schizophrenia therapy, Weltruza. While we were, of course, disappointed by the phase three results for Novartis' Pelacarcin, the overwhelming weight of news across our portfolio was positive, with successful phase three results for Amgen's and Deltra in first-line small cell lung cancer, and Farber is, the Trictivant XR and Hereditary Angioedema. We also structured the Pella Carson investment in a protective way where we will still make our money back plus a small return. As Marshall will explain later, our track record of success in development stage investing remains outstanding. Looking ahead, we're increasing our 2026 full year guidance for the third consecutive quarter based on the excellent business momentum I just highlighted. Slide six is a slide we show every quarter. It demonstrates our consistent double digit growth on average since our IPO. We have delivered this impressive record year in, year out, regardless of the market backdrop. This reflects the quality of our asset selection and our unique business model. It's a track record that I believe very few companies in the healthcare space can match. With that, I will hand it over to Marshall.
You're reading a preview of the RPRX Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing